Gilad Itchaki

1.3k total citations
40 papers, 550 citations indexed

About

Gilad Itchaki is a scholar working on Genetics, Oncology and Hematology. According to data from OpenAlex, Gilad Itchaki has authored 40 papers receiving a total of 550 indexed citations (citations by other indexed papers that have themselves been cited), including 22 papers in Genetics, 12 papers in Oncology and 10 papers in Hematology. Recurrent topics in Gilad Itchaki's work include Chronic Lymphocytic Leukemia Research (21 papers), Lymphoma Diagnosis and Treatment (9 papers) and CAR-T cell therapy research (4 papers). Gilad Itchaki is often cited by papers focused on Chronic Lymphocytic Leukemia Research (21 papers), Lymphoma Diagnosis and Treatment (9 papers) and CAR-T cell therapy research (4 papers). Gilad Itchaki collaborates with scholars based in Israel, United States and Italy. Gilad Itchaki's co-authors include Jennifer R. Brown, Osnat Bairey, Pia Raanani, Tamar Tadmor, Ohad Benjamini, Galia Rahav, Andrei Braester, Lev Shvidel, Najib Dally and Aaron Polliack and has published in prestigious journals such as Blood, Cochrane Database of Systematic Reviews and Cancers.

In The Last Decade

Gilad Itchaki

38 papers receiving 546 citations

Peers

Gilad Itchaki

GENET

ONCOL

PFM

IMMUN

Shankara Paneesha United Kingdom

Sai Ravi Pingali United States

Bénédicte Deau France

Emily Curran United States

Barbara Zdziarska Poland

Christine‐Ivy Liacos Greece

Rosella Matera Italy

Edward Peres United States

Luděk Raida Czechia

Filippo Ballerini Italy

Shankara Paneesha United Kingdom

Gilad Itchaki

154 ×0.6

GENET

186 ×0.8

ONCOL

154 ×0.9

PFM

109 ×0.7

IMMUN

77 ×0.6

Citations per year, relative to Gilad Itchaki Gilad Itchaki (= 1×) peers Shankara Paneesha

Countries citing papers authored by Gilad Itchaki

Since Specialization

Citations

This map shows the geographic impact of Gilad Itchaki's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Gilad Itchaki with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Gilad Itchaki more than expected).

Fields of papers citing papers by Gilad Itchaki

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Gilad Itchaki. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Gilad Itchaki. The network helps show where Gilad Itchaki may publish in the future.

Co-authorship network of co-authors of Gilad Itchaki

This figure shows the co-authorship network connecting the top 25 collaborators of Gilad Itchaki. A scholar is included among the top collaborators of Gilad Itchaki based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Gilad Itchaki. Gilad Itchaki is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Itchaki, Gilad, et al.. (2025). Tumor‐Associated Lactic Acidosis and Early Death in Patients With Lymphoma. Cancer Medicine. 14(7). e70824–e70824. 2 indexed citations

Katzav, Aviva, Debora Kidron, Mario Beiner, et al.. (2024). The selenoenzyme type I iodothyronine deiodinase: a new tumor suppressor in ovarian cancer. Molecular Oncology. 18(9). 2298–2313. 2 indexed citations

Ritter, Amit, Gideon Bachar, Thomas Shpitzer, et al.. (2023). Cutaneous Squamous Cell Carcinoma in Immunocompromised Patients—A Comparison between Different Immunomodulating Conditions. Cancers. 15(6). 1764–1764. 17 indexed citations

Durham, Benjamin H., Oshrat Hershkovitz‐Rokah, Omar Abdel‐Wahab, et al.. (2023). Mutant PIK3CA is a targetable driver alteration in histiocytic neoplasms. Blood Advances. 7(23). 7319–7328. 7 indexed citations

Itchaki, Gilad, et al.. (2023). COVID-19 in Patients with Chronic Lymphocytic Leukemia: What Have We Learned?. Acta Haematologica. 147(1). 60–72. 1 indexed citations

Shimony, Shai, Oren Pasvolsky, Gilad Itchaki, et al.. (2023). Diffuse large B cell lymphoma characteristics and outcomes during the COVID-19 pandemic in two tertiary centers - an Israeli/ Italian study. Annals of Hematology. 103(3). 803–811. 2 indexed citations

Itchaki, Gilad, Ohad Benjamini, Anatoly Nemets, et al.. (2022). "Real-Life" Data of Zanubrutinib in Patients with Waldenström Macroglobulinemia - a Multi-Center Retrospective Study. Blood. 140(Supplement 1). 11981–11982.

Agmon, Inbar Nardi, Ashraf Hamdan, Alon Eisen, et al.. (2021). Diffused coronary involvement in Takayasu arteritis with concomitant malignancy. Clinical Rheumatology. 41(3). 921–928. 4 indexed citations

Itchaki, Gilad, et al.. (2021). Intravascular Lymphoma Mimicking Acute Haemorrhagic Leucoencephalitis. Journal of Neurology and Neuroscience. 12(5).

10.

Gurion, Ronit, Uri Rozovski, Gilad Itchaki, et al.. (2021). Humoral serological response to the BNT162b2 vaccine is abrogated in lymphoma patients within the first 12 months following treatment with anti-CD2O antibodies. Haematologica. 107(3). 715–720. 44 indexed citations

11.

Kasar, Siddha, Aishath Naeem, Svitlana Tyekucheva, et al.. (2021). Activation of the MAPK pathway mediates resistance to PI3K inhibitors in chronic lymphocytic leukemia. Blood. 138(1). 44–56. 43 indexed citations

12.

Benjamini, Ohad, Lior Rokach, Gilad Itchaki, et al.. (2021). Safety and efficacy of the BNT162b mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia. Haematologica. 107(3). 625–634. 73 indexed citations

13.

Luttwak, Efrat, David Hagin, Chava Perry, et al.. (2020). Anti-CD19 CAR-T therapy for EBV-negative posttransplantation lymphoproliferative disease—a single center case series. Bone Marrow Transplantation. 56(5). 1031–1037. 27 indexed citations

14.

Itchaki, Gilad, Toni Dubeau, Andrew Keezer, et al.. (2018). Non-IgM Secreting Lymphoplasmacytic Lymphoma - Experience of a Reference Center for Waldenstrom Macroglobulinemia. Blood. 132(Supplement 1). 2886–2886. 6 indexed citations

15.

Itchaki, Gilad, Grace Tiao, Ma. Reina Improgo, et al.. (2017). Rare Germline Variant in NFATC4 Associated with Familial Chronic Lymphocytic Leukemia. Blood. 130. 2993–2993. 1 indexed citations

16.

Itchaki, Gilad & Jennifer R. Brown. (2017). Lenalidomide in the treatment of chronic lymphocytic leukemia. Expert Opinion on Investigational Drugs. 26(5). 633–650. 33 indexed citations

17.

Muchtar, Eli, Hila Magen, Gilad Itchaki, et al.. (2015). Uninvolved immunoglobulins predicting hematological response in newly diagnosed AL amyloidosis. Leukemia Research. 41. 56–61. 4 indexed citations

18.

Itchaki, Gilad, Moshe Yeshurun, Mical Paul, et al.. (2015). High-Intensity Induction Chemotherapy Is Feasible for Elderly Patients with Acute Myeloid Leukemia. Acta Haematologica. 135(1). 55–64. 4 indexed citations

19.

Wolach, Ofir, Gilad Itchaki, Michal Bar‐Natan, et al.. (2015). High-dose cytarabine as salvage therapy for relapsed or refractory acute myeloid leukemia-is more better or more of the same?. Hematological Oncology. 34(1). 28–35. 10 indexed citations

20.

Shepshelovich, Daniel, Ofer Shpilberg, Meir Lahav, et al.. (2013). Hodgkin Lymphoma and Hypothermia: Case Report and Review of the Literature. Acta Haematologica. 131(4). 227–230. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact